Midcap pharma stocks better than Cipla: Ashish Kapur
Within the pharma space, I think it will be better to go with some of the midcap pharma stocks. Ranbaxy, Cipla are more or less fairly valued.
By 
|
| ET Now spoke to Ashish Kapur, CEO, Invest Shoppe India Ltd on his views on Cipla.
ET Now: How do you view Cipla?
Ashish Kapur: Within the pharma space, I think it will be better to go with some of the midcap pharma stocks. Ranbaxy, Cipla are more or less fairly valued. Chances of making too much money here are quite remote.
ET Now: How do you view Cipla?
Ashish Kapur: Within the pharma space, I think it will be better to go with some of the midcap pharma stocks. Ranbaxy, Cipla are more or less fairly valued. Chances of making too much money here are quite remote.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
